Denali Therapeutics Inc. (DNLI) shares rallied 5.8% in the last trading session to close at $22.63. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.1% gain over the past four weeks. Denali owns an impressive pipeline of targeted therapeutic candidates for neurodegenerative diseases and its recent pipeline progress has been encouraging. Investors are upbeat about the company’s progress with its candidates. ...

First exploration agreement initiated under strategic partnership between Flagship and Pfizer to accelerate the development of innovative medicines Collaboration leverages ProFound's proprietary ProFoundry™ Platform to identify potential novel protein therapeutics from the expanded human proteome ProFound and Pioneering Medicines, Flagship's in-house drug development unit will jointly conduct exploration activities CAMBRIDGE, Mass., June 12, 2024 /PRNewswire/ -- Flagship Pioneering and ProFound™ Therapeutic ...

It has been about a month since the last earnings report for Denali Therapeutics Inc. (DNLI) . Shares have added about 15.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Denali Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Denali Q1 Earnings Mis ...

Denali Therapeutics, Inc. (DNLI) announced that the FDA has selected experimental candidate DNL126 in support of clinical trials advancing the rare disease therapeutics (START) Pilot Program. The candidate is an investigational enzyme replacement therapy designed to cross the blood-brain barrier (BBB) for the potential treatment of MPS IIIA (Sanfilippo syndrome type A). MPS III, also known as Sanfilippo syndrome, is a rare, genetic lysosomal storage disease that causes neurodegeneration. The newly launched ...

文章核心观点 - 公司正在开发一种名为DNL-310的药物,用于治疗MPS II(亨廷顿综合征)患者,并取得了积极的临床试验结果[1][2][4][5][6] - 公司还在开发另一种名为DNL-126的药物,用于治疗MPS IIIA(桑菲利波综合征A型)患者,预计2024年底将公布临床试验数据[3][12] - 公司的目标是开发更多针对不同MPS疾病类型的酶替代疗法[7] - 公司正在与FDA就DNL-310获得加速审批进行讨论,这可能成为一个重要催化剂[10] 财务状况 - 公司截至2024年3月31日拥有14.3亿美元的现金、现金等价物和可流动证券[13] - 公司每季度的现金消耗约为1.322亿美元,现有现金可能无法维持很长时间,需要在未来几个月内进行新一轮融资[14] 风险因素 - DNL-310的2/3期COMPASS试验能否获得加速审批存在不确定性,即使获批也可能无法达到主要终点指标[15] - DNL-126针对MPS IIIA患者的1/2期试验数据能否复制DNL-310的良好结果存在不确定性[16] - DNL-343用于治疗ALS的2/3期HEALEY ALS Platform试验能否取得成功存在不确定性[17][18] - 公司需要进行新一轮融资,这将导致股东权益被摊薄[19]

Denali Therapeutics (DNLI) incurred a first-quarter 2024 loss of 68 cents per share, wider than the Zacks Consensus Estimate of a loss of 67 cents but narrower than the year-ago quarter’s loss of 80 cents. The year-over-year narrower loss was due to a decline in operating expenses. In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations in the top line. Denali did not generate any collaboration revenues in the reported quarter. The Zacks Consensus Estimate for ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38311 Denali Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 46-3872213 (St ...

Exhibit 99.1 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – May 7, 2024 – Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights. "It ...

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights. "It has been an impactful first quarter, and we are excited about multiple opportunities t ...

Denali Therapeutics公司概况 - Denali Therapeutics Inc. (DNLI) 是医疗 - 生物医学和遗传学领域的一个有趣选择[1] - 医疗 - 生物医学和遗传学领域目前处于良好位置，具有良好的行业排名[2] 盈利预期和排名 - 分析师对Denali Therapeutics的盈利预期进行了积极修订，显示出对公司前景的乐观态度[3] - 公司当前的Zacks排名为3（持有），也是一个积极的信号[4]